English Українська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Bilovol A.N., Knyazkova I.I.

    ALDOSTERONE RECEPTOR ANTA-GONISTS: CLINICAL PHARMACOLOGY AND THERAPEUTIC EFFICIENCY IN CHRONICAL HEART FAILURE


    About the author: Bilovol A.N., Knyazkova I.I.
    Heading LITERATURE REVIEWS
    Type of article Обзорная статья
    Annotation In the review іt is marked, that additional assignment of aldosterone receptor antagonists to standard therapy improves survival rate of patients with heavy HF type and left ventricle dysfunction after myocardial infarction. Thus the dynamic control of clinical and biochemical parameters of the patient is obligatory. Close adherence to these recommendations will promote increase of efficiency and decrease drug side effect of aldosterone receptor antago¬nists.
    Tags heart failure, aldosterone receptor antagonists
    Bibliography
    • Беловол А.Н.Ингибиторы ангиотензинпревращающего фермента при хронической сердечной недостаточности: от фармакологических свойств к кли­ническим рекомендациям / А.Н.Беловол, И.И.Князькова // Здоров'я України.- 2010. Кардіологія. -№1.-С.92-94.
    • Беловол А.Н.Терапевтические эффекты блокады альдостерона / А.Н.Беловол, И.И.Князькова // Ліки України. - Серпень 2007.- С. 3-9
    • McMahon E.G. Eplerenone, a new selective aldosterone blocker / E.G. McMahon// Curr. Pharm. Des.- 2003.- Vol.9(13).-P.1065-1075.
    • Struthers A.D. Aldosterone blockade in cardiovascular disease/A.D.Struthers//Heart.- 2004,-Vol.90.-P. 1229-1234.
    • Cohn J.N. Cardiovascular Effects of Aldosterone and Post-Acute Myocar­dial Infarction Pathophysiology / J.N.Cohn, W.Colucci // Am. J. Cardiol. - 2006.- Vol.97.- N 10 (suppl. 1).- P.4-12.
    • Struthers A.D. Review of aldosterone and angiotensin-II-induced target or­gan damage and prevention / A.D.Struthers, T.M.MacDonald // Cardiovasc. Res. - 2004,-Vol.61.-P.663-670.
    • Captopril in heart failure. A double blind controlled trial / J.G.Cleland, HJ.Dargie, G.P.Hodsman et al.// Br. Heart J.- 1984,- Vol.52.- P.530-535.
    • Sato A. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy / A.Sato, T.Saruta // J. Int. Med. Res. -2001,- Vol.29.- P. 13-21.
    • Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors / C.Borghi, S.Boschi, E.Ambrosioni et al. // J. Clin. Pharmacol. - 1993,- Vol.33.- P.40-45.
    • Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators / R.S.McKelvie, S.Yusuf, D.Pericak et al. // Circulation. - 1999,- Vol.100.- P. 1056-1064.
    • Urata H. Mechanisms of angiotensin II formation in humans / H.Urata, H.Nishimura, D.Ganten // Eur. Heart J. - 1995,- Vol.l6(Suppl N).- P.79-85.
    • Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study / P.Vantrimpont, J.L.Rouleau, A.Ciampi et al. // Eur. Heart J. -1998.- Vol.19.- P. 1552-1563.
    • 13 Руководство по кардиологии / Под ред. Ковалеико.-К.; МОРИОН, 2008- 1424 с
    • Karin М. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable / M.Karin // Cell.-1998.- Vol.93.- P.487-90.
    • The effect of spironolactone on morbidity and mortality in patients with se­vere heart failure. Randomized Aldactone Evaluation Study Investigators / B.Pitt, F.Zannad, W.J.Remme et al. //N. Engl. J. Med. - 1999.- Vol.341.- P.709-717.
    • The Pharmacological Basis of Therapeutics / J.G.Hardman, L.E.Limbird, P.B.Molinoff et al. 9th ed. New York: McGraw-Hill; 1996,- P.706-711.
    • Клиническая фармакология по Гудману и Гилману. Под общей редак­цией А.Г.Гилмана, редакторы Дж.Хардман и Л.Лимберд. Пер. с англ.- М.,  Практика, 2006.-1648 с.
    • Muhlberg W. Pharmacokinetics of diuretics in geriatric patients / W. Muhl- berg // Arch. Gerontol. Geriatr. -1989.- Vol. 9.- P.283-90.
    • Nolan P.E. Integrating traditional and emerging treatment options in heart failure/ P.E.Nolan // Am J Health-Syst Pharm.- 2004,- Vol. 61(suppl 2).- P.S14-22.
    • ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collabora­tion with the Heart Failure Association of the ESC (HFA) and endorsed by the Euro­pean Society of Intensive Care Medicine (ESICM) / Task Force Members, K.Dickstein, A.Cohen-Solal, G.Filippatos et al.// Eur. Heart J.- 2008,-Vol. 29(19).- P.2388-2442.
    • 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and man­agement of heart failure in adult: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines devel­oped in collaboration With the International Society for Heart and Lung Transplanta­tion / M.Jessup, W.T.Abraham, D.E.Casey et al. // Circulation. -2009,- Vol.119.- P.1977-2016.
    • Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction / B.Pitt, W.Remme, F.Zannad et al. // N. Engl. J. Med. - 2003,- Vol.348.- P.1309-1321.
    • Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study / D.N.Juurlink, M.M.Mamdani, D.S.Lee et al. // N. Engl. J. Med. - 2004,- Vol.351.-P.543-551
    • Effect of Carvedilol on survival in severe chronic heart failure / M.Packer, A.J.Coats, M.B.Fowler et al. for the Carvedilol Prospective Randomized Comulative Survival Study Group. //N. Engl. J. Med.- 2001.- Vol.344.- P.1651-1658.
    • Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor / T.Kinugawa, K.Ogino, M.Kato et al. // Gen. Pharmacol.- 1998.- Vol.31.- P.93-99.
    • Yee K.M. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure / K.M.Yee, S.D.Pringle, A.D.Struthers //J. Am. Coll. Cardiol.- 2001.- Vol. 37,- P. 1800-1807.
    • Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure / J.Francis, R.M.Weiss, S.G.Wei et al.. //Am. J. Physiol. Heart Circ. Physiol.- 2001,- Vol.281.- P.H2241-H2251.
    • Effect of spironolactone on cardiac sympathetic nerve activity and left ven­tricular remodeling in patients with dilated cardiomyopathy / S.Kasama, T.Toyama, H.Kumakura et al. //J. Am. Coll. Cardiol.- 2003.- Vol.41.- P.574-581.
    • Sackner-Bernstein J.D. Use of carvedilol in chronic heart failure: chal­lenges in therapeutic management / J.D.Sackner-Bernstein // Prog. Cardiovasc. Dis. - 1998,- Vol. 41(1 Suppl 1).- P.53-58.
    Publication of the article «World of Medicine and Biology» №1(32), 2012 year, 13-19 pages, index UDK 616.12-008.64:615